ACUTE PROMYELOCYTIC LEUKEMIA

Chapter 081. Principles of Cancer Treatment (Part 14) Mitomycin C undergoes reduction of its quinone function to generate a bifunctional DNA alkylating agent. It is a broadly active antineoplastic agent with a number of unpredictable toxicities, including delayed bronchospasm 12–14 h after dosing a[r]

and a cut homeodomain (HD) [10]. CUX1 containstwo repressive regions (R1 and R2) at the carboxy ter-minus that account for its repressive activity [11]. Sev-eral Cux1 isoforms are produced from the proteolyticprocessing of p200Cux1 (e.g. p110Cux1) as well asalternative splicing (e.g. p75Cux1) [12].[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 7) Acute Myeloid Leukemia: Treatment Treatment of the newly diagnosed patient with AML is usually divided into two phases, induction and postremission management (Fig. 104-2). The initial goal is to quickly induce CR.[r]

prognosis even if treated with dasatinib or nilotinib. Further Readings AML Frohling S et al: Genetics of myeloid malignancies: Pathogenetic and clinical implications. J Clin Oncol 23:6285, 2005 [PMID: 16155011] National Comprehensive Cancer Network: Acute myeloid leukemia. Clinical Pr[r]

Excess bleeding or bleeding from unusual sites (DIC, thrombocytopenia) Fevers or recurrent infections (granulocytopenia) Headache, vision changes, nonfocal neurologic abnormalities (CNS leukemia or bleed) Early satiety (splenomegaly) Family history of AML (Fanconi, Bloom, or Kostmann syndrome[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 3) Immunophenotype and Relevance to the WHO Classification The immunophenotype of human leukemia cells can be studied by multiparameter flow cytometry after the cells are labeled with monoclonal antibodies to cell-surface an[r]

imatinib-resistant cells. Two drugs have been developed (dasatinib and nilotinib) that are potent inhibitors against most imatinib resistant mutants; these compounds have demonstrated significant activity in patients with imatinib-resistant CML. Table 80-2 FDA-Approved Molecularly Targeted Agents fo[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 2) Table 104-1 Acute Myeloid Leukemia (AML) Classification Systems World Health Organization Classificationa I. AML with recurrent genetic abnormalities AML with t(8;21)(q22;q22);RUNX1/RUNX1T1b AML with abnormal bone[r]

abnormal gene product have been found who do not suffer a relapse. Studies are underway to determine whether a critical threshold level of transcripts uniformly predicts for leukemia relapse. Postremission Therapy Induction of a durable first CR is critical to long-term disease-free survival[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 8) The hematologic toxicity of high-dose cytarabine-based induction regimens has typically been greater than that associated with 7 and 3 regimens. Toxicity with high-dose cytarabine includes myelosuppression, pulmonary toxicity, a[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 6) Most patients are anemic and thrombocytopenic at presentation. Replacement of the appropriate blood components, if necessary, should begin promptly. Because qualitative platelet dysfunction or the presence of an infection may in[r]

DNA laddering in the same representative case depicted in (A).Cavalieri et al. Journal of Translational Medicine 2011, 9:45http://www.translational-medicine.com/content/9/1/45Page 11 of 13Our biochemical data suggest a direct effect on mito-chondrial integrity as a possible mechanism of a-bisabo-lol[r]

Myeloid leukemia may be classified as Acute Myeloid Leukemia (AML) or Chronic Myeloid Leukemia (CML) based on its rate of progression. Administration of drugs is the best modality to treat myeloid leukemia, Imatinib mesylate (IM) and cytarabine (cyt) for CML and AML respectively. However, these drug[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 12) Clinical Presentation Symptoms The clinical onset of the chronic phase is generally insidious. Accordingly, some patients are diagnosed while still asymptomatic, during health-screening tests; other patients present with fatigu[r]

Chapter 104. Acute and Chronic Myeloid Leukemia (Part 11) Chronic Myelogenous Leukemia Incidence The incidence of chronic myelogenous leukemia (CML) is 1.5 per 100,000 people per year, and the age-adjusted incidence is higher in men than in women (2.0 versus 1.2). The in[r]

rupture, or for correction of cytopenias in patients with hypersplenism or immune-mediated destruction of one or more cellular blood elements. Splenectomy is necessary for staging of patients with Hodgkin's disease only in those with clinical stage I or II disease in whom radiation therapy alone is[r]

BBỆỆNH LÝ LAN TNH LÝ LAN TỎỎA A BiBiểểuu hihiệệnn llááchch to + to + thaythay đđổổii đđộộ hhồồii âmâm HH ii âmâm bbììnhnh thưthư ngng: : bb nhnh lýlý tt oo mmááuu, , dd trtr vvàà chuychuy nn hhóóa.a.HH ii âmâm gigi mm: : bb nhnh nhinhi mm trtrùùngng, , lymphoma, leukemialymphoma, leukemia[r]